Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
…, I Mendoza-Hernández, S Fernandez-Castillo… - Vaccine, 2022 - Elsevier
Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
[HTML][HTML] Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with …
…, MM Gouya, A Biglari, S Fernández-Castillo… - The Lancet Regional …, 2023 - thelancet.com
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
[HTML][HTML] Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor …
…, IC Castillo-Quintana, S Fernandez-Castillo… - International Journal of …, 2023 - Elsevier
Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …
[PDF][PDF] Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
…, BL Santos-Vega, S Fernandez-Castillo… - Med, 2022 - cell.com
Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …
OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves
…, JC Dokmetjian, S Fernández Castillo… - Human Vaccines & …, 2018 - Taylor & Francis
Strains of Shiga toxin-producing Escherichia coli (STEC) can cause the severe Hemolytic
Uremic Syndrome (HUS). Shiga toxins are protein toxins that bind and kill microvascular cells, …
Uremic Syndrome (HUS). Shiga toxins are protein toxins that bind and kill microvascular cells, …
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA …
…, A Biglari, P Van der Stuyft, S Fernández-Castillo… - MedRxiv, 2022 - medrxiv.org
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats
…, Y Climent-Ruíz, S Fernández-Castillo… - Toxicology, 2022 - Elsevier
This study evaluates safety of FINLAY-FR-02, a vaccine candidate against SARS-CoV-2 based
on the recombinant receptor binding domain conjugated to tetanus toxoid, in a preclinical…
on the recombinant receptor binding domain conjugated to tetanus toxoid, in a preclinical…
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
…, BL Santos-Vega, S Fernandez-Castillo… - MedRxiv, 2022 - medrxiv.org
Background We report results of immunogenicity, safety and reactogenicity of SOBERANA
02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. …
02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. …
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme.
ME Toledo-Romani, LV Sanchez, MR Gonzalez… - 2021 - pesquisa.bvsalud.org
… Maria Eugenia Toledo-Romani; Leslihana Verdecia Sanchez; Meybis Rodriguez
Gonzalez; Laura Rodriguez Noda; Carmen Valenzuela Silva; Beatriz Paredes Moreno; …
Gonzalez; Laura Rodriguez Noda; Carmen Valenzuela Silva; Beatriz Paredes Moreno; …
[HTML][HTML] Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 …
…, A German-Almeida, S Fernández-Castillo… - The Lancet Regional …, 2024 - thelancet.com
Background Increased pediatric COVID-19 occurrence due to the SARS-CoV-2 Omicron
variant has raised concerns about the effectiveness of existing vaccines. The protection …
variant has raised concerns about the effectiveness of existing vaccines. The protection …
